Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
5.02
-0.14 (-2.71%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Savara Employees
Savara had 70 employees as of December 31, 2025. The number of employees increased by 11 or 18.64% compared to the previous year.
Employees
70
Change (1Y)
11
Growth (1Y)
18.64%
Revenue / Employee
n/a
Profits / Employee
-$1,697,671
Market Cap
1.27B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 749 |
| AbCellera Biologics | 562 |
| Wave Life Sciences | 317 |
| Viridian Therapeutics | 252 |
| Precigen | 160 |
| MapLight Therapeutics | 133 |
| Olema Pharmaceuticals | 131 |
| DBV Technologies | 117 |
SVRA News
- 11 days ago - Savara Announces New Employment Inducement Grant - Business Wire
- 13 days ago - Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 14 days ago - Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference - Business Wire
- 21 days ago - Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 4 weeks ago - Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 6 weeks ago - Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update - Business Wire
- 6 weeks ago - Savara Transcript: The Citizens Life Sciences Conference 2026 - Transcripts
- 7 weeks ago - Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire